期刊文献+

胰十二指肠切除术并发症临床分析 被引量:4

下载PDF
导出
摘要 目的:分析胰十二指肠切除术术后各种并发症发生情况、相关影响因素及预防控制方法。方法:采用回顾性研究方法,对笔者所在医院近年来接受胰十二指肠切除手术的152例患者的临床资料进行整理分析。其中进行壶腹周围恶性肿瘤的根治性切除手术98例,接受联合血管的胰十二指肠切除术54例。结果:152例因各种原因导致胰十二指肠病变而行切除术的患者,其中出现不同程度并发症的患者41例,占26.97%。主要并发症为上消化出血、胰漏、胆漏及胃肠吻合口功能障碍等,其中上消化道出血11例,占并发症总数的26.83%。主要的影响因素为患者的年龄(字2=5.358,P=0.028<0.05)和TBIL量(字2=12.571,P=0.001<0.01)。结论:胰十二指肠切除术术后并发症发生率较高,年龄和TBIL为相关影响因素,术前应对患者进行全面的评估,有效的预防和治疗措施能减少并发症的发生。
作者 刘强
出处 《中外医学研究》 2014年第13期122-123,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
  • 相关文献

参考文献7

  • 1邵堂雷,杨卫平,彭承宏,金筱泰,李宏为.139例胰十二指肠切除术后各种并发症的临床分析[J].中国普通外科杂志,2005,14(11):850-852. 被引量:23
  • 2Lin J W, Gameron J L, Yeo C J, et al.Risk factors and outcomes in post- pancreat cutaneous fistula[J].J Gastroin Test Surg, 2004, 8(10): 951- 959.
  • 3Thomas C, Bottger T C, Junginger T.Factors in fluencing morbidity and mortality after pancreaticoduodenectomy: critical analys is of 221 resections[J].World J Surg, 1999, 23(1): 164-172.
  • 4Schmidt C M, Powell E S, Yiannoutsos C T, et al. a 20-year experience in 516 patients[J].Arch Surg, 2004, 139(7): 718- 725.
  • 5彭淑牖,刘颖斌.胰十二指肠切除术后并发症的处理[J].肝胆胰外科杂志,2001,13(2):57-58. 被引量:37
  • 6Jarufe N P, Coldham C, Mayer A D, et al.Favourable prognostic factors in a large UK experience of the head of pancreas and periampullary region [J].Dig Surg, 2004, 21(3): 202-209.
  • 7Winter J M, Cameron J L, Campbell K A, et a1,1423 for pancreatic cancer: experience[J].J Gastrointest Surg, 2006, 19(9) 1199-1211.

二级参考文献11

共引文献58

同被引文献50

  • 1卢榜裕,陆文奇,李杰,蔡小勇,黄飞,黄玉斌,彭民浩,晏益核.电视腹腔镜胰十二指肠切除术5例报告[J].中国微创外科杂志,2005,5(11):877-879. 被引量:24
  • 2王志才.胰十二指肠切除61例临床分析[J].临床和实验医学杂志,2007,6(10):111-111. 被引量:4
  • 3Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010,60(5):277-300.
  • 4Springett GM, Hoffe SE. Borderline resectable pancreatic cancer : on the edge of survival [ J ]. Cancer Control, 2008, 15 ( 4 ) : 295 -307.
  • 5Vincent A, Herman J, Schulick R, et al. Pancreatic cancer[J]. Lancet, 2011,378(9791 ) :607-620.
  • 6Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy [ J ]. Ann Surg Oncol, 2006, 13 ( 8 ) : 1035 -1046.
  • 7Gillen S, Schuster T, Meyer Zum Btischenfelde C, et al. Preope- rative/neoadjuvant therapy in pancreatic cancer: a systematic re- view and metaanalysls of response and resection percentages J ]. PLoS Med, 2010,7(4) :e1000267.
  • 8Talamonti MS, Small W Jr, Mulcahy MF, et al. A muhi-institu- tional phase l/ trial of preoperative full-dose gemcitabine and con- currentradiation for patients with pote-ntially resectable pancreatic carcinoma[ J]. Ann Surg Oncol, 2006,13 (2) : 150-158.
  • 9Araujo RL, Gaujoux S, Huguet F, et al. Does pre-operative che- moradiation for init-ially unresectable or borderline resectable pan- ereatic adenoeareinoma increase post-operative morbidity? a case- matched analysis[ J]. HPB (Oxford) , 2013,15 (8) :574-580.
  • 10SahoraK, Schindl M, Kuehrer I, et al. Gemcitabine-based neoad- juvant chemo-therapy for locally advanced pancreatic cancer does not affect mortality and morbidity after pancreatic resection [ J ]. European Surgery, 2013,45(3) :169-178.

引证文献4

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部